Stoke Historical Balance Sheet

STOK Stock

USD 7.40 0.34 4.39%

Trend analysis of Stoke Therapeutics balance sheet accounts such as Other Liabilities of 44.8 M, Net Tangible Assets of 186.4 M, Property Plant And Equipment Net of 6.8 M or Total Permanent Equity of 0.0 provides information on Stoke Therapeutics' total assets, liabilities, and equity, which is the actual value of Stoke Therapeutics to its prevalent stockholders. By breaking down trends over time using Stoke Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Stoke Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Stoke Therapeutics is a good buy for the upcoming year.

Stoke Therapeutics Inventory

10.33 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

About Stoke Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Stoke Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Stoke Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Stoke Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Stoke currently owns. An asset can also be divided into two categories, current and non-current.

Stoke Therapeutics Balance Sheet Chart

At this time, Stoke Therapeutics' Inventory is quite stable compared to the past year. Net Working Capital is expected to rise to about 193.6 M this year, although the value of Total Stockholder Equity will most likely fall to about 193.3 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Stoke Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Stoke Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Stoke Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Stoke Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Stoke Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Stoke Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.At this time, Stoke Therapeutics' Inventory is quite stable compared to the past year. Net Working Capital is expected to rise to about 193.6 M this year, although the value of Total Stockholder Equity will most likely fall to about 193.3 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	13.4M	11.8M	16.2M	9.9M
Total Assets	256.1M	228.3M	271.6M	224.3M

Other Current Liab Total Assets

Stoke Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.8	0.73	0.99	0.63	0.99	0.81	-0.92	-0.75	0.85	0.92	0.62	0.42	0.27	1.0	0.88	0.45	0.96	0.86	0.93	0.67	0.99	0.75	1.0	0.69	0.99
Other Current Liab	0.8		0.88	0.72	0.79	0.72	0.91	-0.53	-0.88	0.83	0.54	0.74	0.53	0.37	0.75	0.93	0.56	0.91	0.96	0.92	0.83	0.72	0.9	0.77	0.86	0.72
Total Current Liabilities	0.73	0.88		0.64	0.97	0.64	0.85	-0.46	-0.99	0.73	0.51	0.92	0.77	0.08	0.68	0.89	0.55	0.82	0.91	0.87	0.84	0.64	0.89	0.7	0.78	0.65
Total Stockholder Equity	0.99	0.72	0.64		0.53	1.0	0.71	-0.94	-0.67	0.85	0.95	0.57	0.41	0.29	0.99	0.82	0.31	0.91	0.78	0.88	0.54	1.0	0.66	0.99	0.6	0.99
Other Liab	0.63	0.79	0.97	0.53		0.53	0.82	-0.36	-0.96	0.6	0.41	0.88	0.73	-0.09	0.58	0.83	0.62	0.74	0.86	0.81	0.87	0.53	0.87	0.6	0.74	0.54
Net Tangible Assets	0.99	0.72	0.64	1.0	0.53		0.73	-0.96	-0.67	0.84	0.96	0.55	0.37	0.29	1.0	0.82	0.36	0.92	0.78	0.88	0.56	1.0	0.67	0.99	0.62	1.0
Property Plant And Equipment Net	0.81	0.91	0.85	0.71	0.82	0.73		-0.6	-0.86	0.77	0.61	0.63	0.36	0.33	0.78	0.9	0.79	0.91	0.96	0.9	0.94	0.71	0.94	0.79	0.96	0.75
Net Debt	-0.92	-0.53	-0.46	-0.94	-0.36	-0.96	-0.6		0.51	-0.72	-1.0	-0.36	-0.2	-0.17	-0.94	-0.68	-0.31	-0.81	-0.63	-0.76	-0.44	-0.94	-0.54	-0.93	-0.49	-0.95
Retained Earnings	-0.75	-0.88	-0.99	-0.67	-0.96	-0.67	-0.86	0.51		-0.78	-0.55	-0.92	-0.77	-0.1	-0.7	-0.92	-0.53	-0.84	-0.92	-0.9	-0.83	-0.67	-0.93	-0.72	-0.81	-0.67
Accounts Payable	0.85	0.83	0.73	0.85	0.6	0.84	0.77	-0.72	-0.78		0.73	0.7	0.54	0.5	0.83	0.91	0.25	0.88	0.82	0.9	0.56	0.85	0.8	0.83	0.76	0.81
Cash	0.92	0.54	0.51	0.95	0.41	0.96	0.61	-1.0	-0.55	0.73		0.42	0.26	0.17	0.95	0.69	0.3	0.81	0.65	0.77	0.45	0.95	0.56	0.94	0.51	0.96
Non Current Assets Total	0.62	0.74	0.92	0.57	0.88	0.55	0.63	-0.36	-0.92	0.7	0.42		0.95	0.04	0.57	0.78	0.2	0.67	0.74	0.76	0.58	0.57	0.73	0.58	0.57	0.54
Non Currrent Assets Other	0.42	0.53	0.77	0.41	0.73	0.37	0.36	-0.2	-0.77	0.54	0.26	0.95		-0.09	0.37	0.59	-0.08	0.45	0.51	0.56	0.33	0.41	0.51	0.38	0.3	0.35
Other Assets	0.27	0.37	0.08	0.29	-0.09	0.29	0.33	-0.17	-0.1	0.5	0.17	0.04	-0.09		0.27	0.24	-0.03	0.28	0.22	0.22	0.04	0.29	0.18	0.27	0.47	0.28
Cash And Short Term Investments	1.0	0.75	0.68	0.99	0.58	1.0	0.78	-0.94	-0.7	0.83	0.95	0.57	0.37	0.27		0.84	0.43	0.94	0.82	0.9	0.63	0.99	0.7	1.0	0.66	1.0
Common Stock Shares Outstanding	0.88	0.93	0.89	0.82	0.83	0.82	0.9	-0.68	-0.92	0.91	0.69	0.78	0.59	0.24	0.84		0.54	0.96	0.97	0.98	0.82	0.82	0.94	0.85	0.84	0.81
Non Current Liabilities Total	0.45	0.56	0.55	0.31	0.62	0.36	0.79	-0.31	-0.53	0.25	0.3	0.2	-0.08	-0.03	0.43	0.54		0.58	0.69	0.54	0.9	0.31	0.69	0.45	0.73	0.4
Capital Surpluse	0.96	0.91	0.82	0.91	0.74	0.92	0.91	-0.81	-0.84	0.88	0.81	0.67	0.45	0.28	0.94	0.96	0.58		0.96	0.99	0.81	0.91	0.89	0.95	0.82	0.92
Other Current Assets	0.86	0.96	0.91	0.78	0.86	0.78	0.96	-0.63	-0.92	0.82	0.65	0.74	0.51	0.22	0.82	0.97	0.69	0.96		0.97	0.92	0.78	0.96	0.84	0.89	0.79
Other Stockholder Equity	0.93	0.92	0.87	0.88	0.81	0.88	0.9	-0.76	-0.9	0.9	0.77	0.76	0.56	0.22	0.9	0.98	0.54	0.99	0.97		0.81	0.88	0.93	0.91	0.82	0.88
Total Liab	0.67	0.83	0.84	0.54	0.87	0.56	0.94	-0.44	-0.83	0.56	0.45	0.58	0.33	0.04	0.63	0.82	0.9	0.81	0.92	0.81		0.54	0.91	0.65	0.87	0.59
Net Invested Capital	0.99	0.72	0.64	1.0	0.53	1.0	0.71	-0.94	-0.67	0.85	0.95	0.57	0.41	0.29	0.99	0.82	0.31	0.91	0.78	0.88	0.54		0.66	0.99	0.6	0.99
Property Plant And Equipment Gross	0.75	0.9	0.89	0.66	0.87	0.67	0.94	-0.54	-0.93	0.8	0.56	0.73	0.51	0.18	0.7	0.94	0.69	0.89	0.96	0.93	0.91	0.66		0.72	0.92	0.67
Total Current Assets	1.0	0.77	0.7	0.99	0.6	0.99	0.79	-0.93	-0.72	0.83	0.94	0.58	0.38	0.27	1.0	0.85	0.45	0.95	0.84	0.91	0.65	0.99	0.72		0.68	1.0
Non Current Liabilities Other	0.69	0.86	0.78	0.6	0.74	0.62	0.96	-0.49	-0.81	0.76	0.51	0.57	0.3	0.47	0.66	0.84	0.73	0.82	0.89	0.82	0.87	0.6	0.92	0.68		0.63
Net Working Capital	0.99	0.72	0.65	0.99	0.54	1.0	0.75	-0.95	-0.67	0.81	0.96	0.54	0.35	0.28	1.0	0.81	0.4	0.92	0.79	0.88	0.59	0.99	0.67	1.0	0.63

Click cells to compare fundamentals

Stoke Therapeutics Account Relationship Matchups

Stoke Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	297.9M	238.9M	256.1M	228.3M	271.6M	224.3M
Other Current Liab	8.9M	13.2M	13.4M	11.8M	16.2M	9.9M
Total Current Liabilities	11.4M	17.1M	31.4M	30.8M	40.1M	42.1M
Total Stockholder Equity	286.1M	217.8M	184.8M	159.6M	229.0M	193.3M
Other Liab	221K	342K	3.9M	37.1M	42.7M	44.8M
Net Tangible Assets	224.4M	286.1M	217.8M	184.8M	212.6M	186.4M
Property Plant And Equipment Net	3.8M	9.1M	11.4M	12.4M	8.3M	6.8M
Net Debt	(287.2M)	(143.4M)	(111.2M)	(189.4M)	(125.7M)	(131.9M)
Retained Earnings	(110.3M)	(196.1M)	(297.2M)	(401.8M)	(490.8M)	(466.3M)
Accounts Payable	1.5M	2.4M	766K	1.7M	2.5M	1.5M
Cash	287.3M	144.9M	113.6M	191.4M	128.0M	164.3M
Non Current Assets Total	4.0M	9.6M	12.0M	13.0M	38.8M	40.7M
Other Assets	205K	1.3M	248.5M	569K	654.4K	621.6K
Cash And Short Term Investments	287.3M	219.8M	229.6M	201.4M	216.9M	204.1M
Common Stock Shares Outstanding	33.5M	36.7M	38.9M	44.0M	54.0M	35.9M
Liabilities And Stockholders Equity	297.9M	238.9M	256.1M	228.3M	271.6M	224.3M
Non Current Liabilities Total	422K	3.9M	39.8M	38.0M	2.5M	2.4M
Capital Surpluse	282.5M	396.4M	414.0M	483.2M	555.6M	315.1M
Other Current Assets	6.6M	9.3M	13.9M	13.9M	15.2M	8.6M
Other Stockholder Equity	396.4M	414.0M	483.2M	561.4M	720.0M	412.6M
Total Liab	11.8M	21.1M	71.2M	68.8M	42.5M	31.1M
Net Invested Capital	286.1M	217.8M	184.8M	159.6M	229.0M	193.3M
Property Plant And Equipment Gross	3.8M	9.1M	11.4M	19.1M	17.1M	8.9M
Total Current Assets	293.9M	229.2M	244.1M	215.3M	232.8M	213.0M
Non Current Liabilities Other	422K	3.9M	3.0M	4.9M	2.5M	2.1M
Net Working Capital	282.5M	212.1M	212.7M	184.5M	192.7M	193.6M
Property Plant Equipment	2.5M	2.7M	9.1M	6.7M	7.7M	4.1M
Net Receivables	6K	132K	588K	64K	700K	735K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:

How To Invest In Stoke

Details

Is Stoke Stock a good investment?

Details

What is Stoke Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.65)

Revenue Per Share

0.677

Quarterly Revenue Growth

7.071

Return On Assets

(0.25)

Return On Equity

(0.46)

The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Stoke Historical Balance Sheet

Stoke Therapeutics Inventory

10.33 Million

About Stoke Balance Sheet Analysis

Stoke Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Stoke Therapeutics balance sheet Correlations

Stoke Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Stoke Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Net Tangible Assets
Net Invested Capital	+ 1.0	Net Tangible Assets

Cash	- 1.0	Net Debt
Retained Earnings	- 0.99	Total Current Liabilities
Net Debt	- 0.96	Net Tangible Assets
Retained Earnings	- 0.96	Other Liab
Net Working Capital	- 0.95	Net Debt
Net Invested Capital	- 0.94	Net Debt